The trial in Boston federal court is one of a handful to have taken place since the U.S. Supreme Court in 2013 said so-called“pay-for-delay” settlements resolving pharmaceutical patent lawsuits can violate antitrust laws. The settlements occur when a brand-name drugmaker pays a generic rival to delay …
